BIOPHARMA, BIOTECH AND MEDTECH
We describe ourselves as a new breed life sciences advisory firm which operates at the nexus of innovative medicines, data & digital technology, and new business models to reimagine existing processes across the drug value chain and create new competitive advantages for our pharma, biotech and medtech customers. Our customers today work with us across drug discovery, drug-product commercialization, drug-product life cycle management, drug supply chain management, cold chain, and beyond the molecule initiatives.
Strategy
The most exceptional opportunity is meaningless without a robust strategy that can be executed with precision, forming the bridge between vision and outcome. Our customers today leverage our strategic services across drug development & manufacturing, drug-product commercialization, drug-product life cycle management, cold chain, drug dispensing, and beyond the molecule initiatives.
Strategic services offered at both global and business unit level include:
- Corporate strategy
- Digital health & digital medicines strategy
- Commercial strategy and sales transformation
- Product launch
- Market expansion
- Pricing strategy
- Revenue optimization
- Sustainability business strategy
- Go-to-market strategy
Entrepreneur in residence
The ability to embed external thinking and doing into your organization in an agile and dynamic manner is key to successful transformations and growth. At Reformulate, we can provide you with experienced senior executives who are ‘entrepreneurs in residence’ in your organization.
Our ‘entrepreneur in residence’ will form a key part of your team for a period as short or as long as needed. Services include:
- Building teams for digital transformation
- Helping to frame, design and execute solutions
- Developing internal and external presentations
- Leading discussions with key external stakeholders
- Building a culture of innovation
Sector Reviews
As new technological paradigms mature and value propositions shift to drive long-term healthcare value and impact, it is critical that life science companies stay at the forefront of industry shifts and changes. We help clients to become and stay deeply immersed in the current state of the industry and where it is heading, allowing them to more effectively allocate resources and determine strategic priorities.
Coverage can include:
- Competitive landscape
- Market size and growth
- Industry dynamics and drivers
- Emerging technologies
- Growth opportunities
- Regulatory environment
- Risks
Market Sizing
Exploring new markets and staying well versed across the development of currently penetrated markets involves performing detailed sizings of both the addressable and total market. Our market sizings provide clients with a clear view as to size of the potential opportunity or remaining growth potential, and transcend numbers to clearly illustrate the ‘so what’ and the courses of action to success.
We leverage a number of primary and secondary sources to inform the sizing including expert & KOL interviews, internal company data and external industry reports & data.
Coverage includes:
- Addressable market size and growth
- Total market size and growth
- Size by segment
Opportunity Assessment
Robust opportunity assessment is critical to the identification and development of scalable solutions that enhance therapeutic area revenue across the drug value chain. As part of the assessment, several dimensions must be explored to provide an accurate view as to the attractiveness of the opportunity, including size, risks, competitor landscape & positioning, and required capabilities to execute.
For example:
- Assessing the commercial attractiveness of a new life sciences digital product
- Evaluating a potential merger, acquisition or joint venture opportunity
OUR NOVEL DIGITAL & DATA PORTFOLIO STRATEGY
combines the culture, people, strategy, go-to-market capabilities, and partnerships required to focus on the solution design, implementation approach, and capital efficient business models, in lieu of the technology alone.
Enhancing The Drug Value Chain
by augmenting existing processes with a new generation of scalability-by-design digital core, digital UX and digital health solutions.
Reformulating Biopharma’s Digital Health Strategy
In this article our CEO Dr Ramin Rafiei explains how the convergence of conventional information technology & biotechnology is accelerating digital transformation across the drug value chain, and those that figure out how to harness it effectively will derive a disproportional competitive advantage.
